Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT)-Reference-Cited by-同舟云学术

Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT)

Published:2022-08 Issue: Volume:171 Page:75-84
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ternov Klara K.,Sønksen Jens,Fode Mikkel,Lindberg Henriette,Kistorp Caroline,Bisbjerg Rasmus,Faber Jens,Klausen Tobias W.,Palapattu Ganesh,Østergren Peter B.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study;Østergren;BJU Int,2019

2. The use of exercise interventions to overcome adverse effects of androgen deprivation therapy;Østergren;Nat Rev Urol,2016

3. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer;Annala;Cancer Discov,2018

4. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate;Tagawa;Prostate Cancer Prostatic Dis,2021

5. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis;Sathianathen;Eur Urol,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-05

3. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy;European Urology Oncology;2024-06

4. Ligand‐gated ion channels as potential biomarkers for ADT‐mediated cognitive decline in prostate cancer patients;Molecular Carcinogenesis;2024-03-14

5. Changes in Quality of Life and Sexual Function After Luteinizing Hormone‐Releasing Hormone (LHRH) Agonists and Orchiectomy in Men With Metastatic Prostate Cancer: Results From a Randomized Trial;Cureus;2024-03-11